#USA #San Diego #CellarisBio #Challenging Target Award #MICRO-TAG

CellarisBio's New Initiative in Drug Discovery

CellarisBio, a techbio company based in San Diego, is set to revolutionize the drug discovery landscape with the introduction of the 'Challenging Target Award'. Announced on December 16, 2024, this award aims to inspire and propel innovation within the realm of challenging therapeutic targets—those proteins which have historically been deemed 'undruggable'. The awards program is scheduled to kick-off on January 15, 2025, with the winner to be revealed on April 15, 2025.

The primary objective of the Challenging Target Award is to de-risk and accelerate the discovery of first-in-class and best-in-class drugs. Participants of the award will gain exclusive access to CellarisBio's MICRO-TAG™ cell target engagement platform. This platform is designed for real-time analysis, enabling hit-to-lead optimization and facilitating mechanism-of-action studies through the use of DNA-Encoded Libraries (DELs).

Elmar Nurmemmedov, co-founder and CEO of CellarisBio, has expressed the company's commitment to expanding the druggable proteome and unlocking valuable therapies that may otherwise remain undiscovered. He stated, “Our mission is to tackle the more than 9,000 undiscovered therapies obstructed by challenging drug targets. We are dedicated to collaborating with like-minded biotechs to pave the way for the assembly of future life-saving therapies.”

The award is particularly notable not just for its financial implications but for the unique technological capabilities it offers. As Ivan Babic, another co-founder, mentions, there has been a paradigm shift in drug discovery technologies, making it critical to employ live cells as filters. This method minimizes risk while enhancing the likelihood of successful outcomes. Babic emphasizes that demonstrating direct drug target engagement within a cellular context is vital for understanding drug pharmacology.

The application process for the Challenging Target Award will be accessible via the CellarisBio website. Participants of diverse backgrounds and expertise will have the opportunity to submit their proposals, provided they are working on innovative approaches to target these challenging proteins.

CellarisBio itself is making waves in the techbio sector with its innovative approaches. Founded and operating from Biovista labs in San Diego, the company maintains several patents protecting its leading-edge technology. Their commitment to advancing partnerships worldwide signifies a strategic effort to enrich the drug discovery ecosystem.

As the field of drug discovery progresses, initiatives like the Challenging Target Award become increasingly essential for fostering collaboration and innovation. By leveraging advanced technologies and methodologies, CellarisBio aims to bridge the gap between research and practical therapeutic solutions.

For further information on the award and to keep updated on developments, interested parties can visit CellarisBio's official site. The company's proactive approach in engaging with the scientific community underscores the urgency in tackling the healing potential of previously overlooked drug targets.

About CellarisBio
CellarisBio stands at the forefront of the techbio domain, developing next-generation technologies that redefine cell target engagement. With an emphasis on innovation, the company is reshaping the landscape of drug discovery, aiming to unlock critical therapeutic interventions in the healthcare industry.